Next Issue
Volume 14, January
Previous Issue
Volume 13, November
 
 

Vaccines, Volume 13, Issue 12 (December 2025) – 82 articles

Cover Story (view full-size image): Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports. Our aim is to encourage scientists to publish their experimental and theoretical results in open access form in as much detail as possible. The full experimental details must be provided so that the results can be reproduced and computed data or files regarding the full details of the experimental procedure can be deposited as supplementary material.
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Select all
Export citation of selected articles as:
19 pages, 3361 KB  
Article
Immunogenicity of Sulfated Lactosyl Archaeol Archaeosome-Adjuvanted Versus Non-Adjuvanted SARS-CoV-2 Spike Booster Vaccines in Young and Aged Balb/c Mice
by Felicity C. Stark, Bassel Akache, Tyler M. Renner, Gerard Agbayani, Lise Deschatelets, Renu Dudani, Blair A. Harrison, Usha D. Hemraz, Sophie Régnier, Matthew Stuible, Yves Durocher and Michael J. McCluskie
Vaccines 2025, 13(12), 1257; https://doi.org/10.3390/vaccines13121257 - 18 Dec 2025
Viewed by 332
Abstract
Background/Objectives: The rise of immune escape variants of the SARS-CoV-2 virus has prompted the development of vaccines based on the variant’s spike antigen sequence. Since variant-specific SARS-CoV-2 vaccines are mostly administered as boosters to individuals previously vaccinated with reference (Ref.) strain-based vaccines, a [...] Read more.
Background/Objectives: The rise of immune escape variants of the SARS-CoV-2 virus has prompted the development of vaccines based on the variant’s spike antigen sequence. Since variant-specific SARS-CoV-2 vaccines are mostly administered as boosters to individuals previously vaccinated with reference (Ref.) strain-based vaccines, a better understanding of their immunogenicity in this context is essential. Protein subunit vaccines have a well-established track record of safety. Herein, we assessed the ability of variant-specific protein subunit vaccine formulations to boost pre-existing Ref. strain-specific immune responses compared to boosting with a Ref. strain-specific formulation in young and aged female Balb/c mice. Methods: Following a priming vaccination series with Ref. spike protein adjuvanted with sulfated lactosyl archaeol (SLA) archaeosomes on days 0 and 21, immune responses were evaluated in young and aged female Balb/c mice. On day 91, mice received a third immunization with Ref., Beta, or Delta spike protein formulations, with or without SLA archaeosomes. Antibody titers, neutralization activity, and cellular immune responses were measured to assess the impact of the booster formulation. Results: Aged mice exhibited lower antibody titers throughout the study and a decline over time compared to young mice. After a third immunization, responses were boosted by all vaccine formulations (Ref., Beta, or Delta), with or without adjuvant. However, variant-specific antigen formulations did not overcome immune imprinting from the priming series or increase neutralization activity against the corresponding SARS-CoV-2 variants in either age group. Conclusions: Variant-specific protein subunit vaccines enhanced immune responses but did not overcome immune imprinting induced by the Ref. strain’s priming. The inclusion of SLA archaeosomes improved cellular immunity, supporting their potential role in optimizing booster vaccine performance, particularly in aged populations. Full article
(This article belongs to the Special Issue Novel Vaccines and Vaccine Technologies for Emerging Infections)
Show Figures

Figure 1

12 pages, 224 KB  
Article
Socioeconomic Disparities in Childhood Vaccination Coverage in the United States: Evidence from a Post-COVID-19 Birth Cohort
by Xiaoyang Lv, Antong Long, Yansheng Chen and Hai Fang
Vaccines 2025, 13(12), 1256; https://doi.org/10.3390/vaccines13121256 - 18 Dec 2025
Viewed by 456
Abstract
Background: Childhood immunization is one of the most effective public health strategies for reducing morbidity and mortality from vaccine-preventable diseases. Although overall vaccination coverage in the United States remains high, disparities persist across socioeconomic and healthcare access groups. Understanding these disparities is [...] Read more.
Background: Childhood immunization is one of the most effective public health strategies for reducing morbidity and mortality from vaccine-preventable diseases. Although overall vaccination coverage in the United States remains high, disparities persist across socioeconomic and healthcare access groups. Understanding these disparities is particularly important in the post-COVID-19 era, when increased vaccine hesitancy may threaten progress in maintaining equitable coverage. Materials and Methods: We analyzed data from the National Immunization Survey–Child (NIS-Child), focusing on U.S. children aged 19–35 months in 2023, corresponding to cohorts reaching this age during or after the COVID-19 pandemic. The primary outcome was receipt of the up-to-date combined 7-vaccine series (4:3:1:3:3:1:3: ≥4 doses of DTaP, ≥3 doses of polio, ≥1 dose of measles-containing vaccine, full Hib series, ≥3 doses of hepatitis B, ≥1 dose of varicella, and ≥3 doses of PCV). Logistic regression models were used to estimate associations between vaccination coverage and key explanatory variables: household income-to-poverty ratio, maternal education, health insurance type, and provider facility type, controlling for demographic and regional covariates. Disparities were quantified using concentration indices (CIs). Results: Among children in the analytic sample, overall coverage for the 7-vaccine series was only 78.5%. Nonetheless, disparities were evident. Children from households with lower income-to-poverty ratios (<1 × FPL: OR = 0.44, 95% CI = 0.37–0.53; 100–200%: OR = 0.66, 95% CI = 0.56–0.79), those covered by Medicaid (OR = 0.54, 95% CI = 0.45–0.64), other insurance (OR = 0.48, 95% CI = 0.37–0.61), or uninsured (OR = 0.27, 95% CI = 0.18–0.42), and those whose mothers had lower educational attainment (<12 years: OR = 0.35, 95% CI = 0.28–0.44) had significantly lower odds of being up-to-date. Similar associations were observed across specific vaccines. Unadjusted CIs for income-to-poverty ratio (0.04, p < 0.01), maternal education (0.04, p < 0.01), health insurance (0.03, p < 0.01), and provider type (0.03, p < 0.01) decreased but remained statistically significant after adjustment (0.02, 0.02, 0.01, and 0.02, respectively; all p < 0.01). No significant disparities were found by census region or race/ethnicity. Discussion: Despite relatively high overall vaccination coverage among U.S. children born during and after the COVID-19 pandemic, disparities by socioeconomic and healthcare access factors persisted. However, the absolute magnitude of these disparities was very small (concentration indices ≤ 0.04). These findings suggest that while inequities remain statistically measurable, their scale is limited in absolute terms. Targeted efforts to address income, insurance, maternal education, and provider-related barriers will be important to sustain equitable immunization coverage in the post-pandemic era. Full article
16 pages, 1283 KB  
Article
Socioeconomic Barriers to COVID-19 Booster Vaccination in Southern Italy: A Retrospective Study to Evaluate Association with the Social and Material Vulnerability Index in Apulia
by Nicola Bartolomeo, Letizia Lorusso, Niccolò Maldera and Paolo Trerotoli
Vaccines 2025, 13(12), 1255; https://doi.org/10.3390/vaccines13121255 - 18 Dec 2025
Viewed by 630
Abstract
Background: Socioeconomic disparities may affect COVID-19 booster vaccination uptake, potentially undermining public health efforts. This study assessed the association between first booster dose coverage and municipal socioeconomic deprivation in the Apulia region of southern Italy. A secondary objective was to evaluate whether [...] Read more.
Background: Socioeconomic disparities may affect COVID-19 booster vaccination uptake, potentially undermining public health efforts. This study assessed the association between first booster dose coverage and municipal socioeconomic deprivation in the Apulia region of southern Italy. A secondary objective was to evaluate whether SARS-CoV-2 incidence modified this relationship. Methods: We conducted a retrospective observational study including Apulian residents aged ≥5 years from 1 January 2021, to 31 December 2022. First booster doses were identified using an algorithm based on dose chronology and national guidelines. Vaccination and infection data were retrieved from regional databases. Socioeconomic deprivation was measured using the Social and Material Vulnerability Index (SMVI) developed by the Italian National Institute of Statistics (ISTAT). Booster coverage was calculated at the municipal level. A multivariable Poisson’s regression model was used to estimate the association between SMVI and booster uptake, adjusting for age group, primary vaccine type, SARS-CoV-2 incidence, and municipal vaccination rates. Analyses were stratified by sex. Results: A total of 2,732,258 individuals received a first booster dose. Booster coverage decreased with increasing SMVI. Among females, a significant reduction was observed in the highest deprivation category (RR > 102 vs. <99: 0.95; 95% CI: 0.94–0.97) and it was similar in males (RR: 0.95; 95% CI: 0.93–0.96). A significant interaction between age and deprivation was found in both sexes, with a sharper decline in younger individuals. Municipal vaccination rates were positively associated with booster uptake. SARS-CoV-2 incidence was positively associated with uptake only in males. Conclusions: The analysis revealed a significant association between lower socio-cultural level and lower adherence to the first booster dose of the COVID-19 vaccine. The decline is more pronounced among subjects younger than 50 years with high levels of vulnerability. The findings of this study suggest that to overthrow vaccine hesitancy, knowledge of the social setting allows for targeted communications to the different groups in the population. Further research is needed to define different approaches in the different social groups. Full article
Show Figures

Figure 1

24 pages, 422 KB  
Review
Competing Theories on Global and Regional Vaccine Inequities: A Scoping Literature Review Within the Context of the COVID-19 Pandemic
by Karl Philipp Puchner, Elias Kondilis, Nasia Palantza, Stergios Seretis, Stavros Mavroudeas, Alexis Benos and Dimitris Papamichail
Vaccines 2025, 13(12), 1254; https://doi.org/10.3390/vaccines13121254 - 17 Dec 2025
Viewed by 463
Abstract
Background/Objectives: Despite global efforts, COVID-19 revealed severe spatial vaccine inequities, disproportionately affecting low- and middle-income countries (LMICs). Scholars across disciplines proposed numerous—and often competing—terms and theories to explain these disparities. In this review and within the context of the COVID-19 pandemic, we [...] Read more.
Background/Objectives: Despite global efforts, COVID-19 revealed severe spatial vaccine inequities, disproportionately affecting low- and middle-income countries (LMICs). Scholars across disciplines proposed numerous—and often competing—terms and theories to explain these disparities. In this review and within the context of the COVID-19 pandemic, we assess the usage, definition, and appropriateness of these terms and their linked theories or frameworks. Methods: We conducted a scoping review aiming to clarify key definitions, concepts, and frameworks of eight prominent terms used in the literature regarding COVID-19 global and/or regional vaccine inequities (i.e., vaccine nationalism, vaccine apartheid, vaccine colonialism, vaccine imperialism, vaccine racism, vaccine diplomacy, vaccine solidarity, and vaccine internationalism). The methodology followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines for Scoping Reviews and included papers from January 2020 to the end of October 2024. Results: We included 79 papers in our study. The majority (71%) were published in 2021–2022, with less than one-quarter authored by scholars from LMICs. Vaccine imperialism was consistently defined but rarely used, while vaccine nationalism and vaccine apartheid appeared more frequently with varied meanings. Yet, in most cases, all of these concepts identified economic interests of vaccine-producing countries as the root cause of the observed vaccine inequities. Vaccine diplomacy showed similar ambiguity, viewed by some as worsening inequities and by others as potentially mitigating them. The terms vaccine racism, vaccine colonialism, and vaccine solidarity were not explicitly identified but appear to be embedded within the definitions of other prominent terms detected. Conclusions: Across the preselected terms examined, we found numerous—and often conflicting—definitions, revealing the fragmented and competing understandings of the major drivers fueling global vaccine inequities. This lack of coherence inhibits evidence synthesis or shared theoretical progress but, most importantly, might undermine current and future efforts to address these inequities. Full article
Show Figures

Figure 1

15 pages, 1034 KB  
Article
Booster Vaccination Against Invasive Pneumococcal Disease and Hepatitis B in Previously Vaccinated Solid Organ Transplant Recipients Without Seroprotection
by Julie Sejerøe-Olsen, Moises Alberto Suarez-Zdunek, Thomas Helbo, Lise Bank Hornung, Charlotte Sværke Jørgensen, Kasper Rossing, Michael Perch, Allan Rasmussen, Sebastian Rask Hamm and Susanne Dam Nielsen
Vaccines 2025, 13(12), 1253; https://doi.org/10.3390/vaccines13121253 - 17 Dec 2025
Viewed by 453
Abstract
Background: Despite pre-transplantation vaccination against invasive pneumococcal disease (IPD) and hepatitis B virus (HBV), most solid organ transplant (SOT) recipients are without post-transplantation seroprotection against IPD and HBV. We aimed to determine the seroprotection rates and changes in antibody concentrations after booster vaccination [...] Read more.
Background: Despite pre-transplantation vaccination against invasive pneumococcal disease (IPD) and hepatitis B virus (HBV), most solid organ transplant (SOT) recipients are without post-transplantation seroprotection against IPD and HBV. We aimed to determine the seroprotection rates and changes in antibody concentrations after booster vaccination against IPD and HBV in SOT recipients without post-transplantation seroprotection after pre-transplantation vaccination. Furthermore, we aimed to identify risk factors associated with non-response to booster vaccination. Methods: In this prospective cohort study, we included adult SOT recipients without post-transplantation seroprotection against IPD who then received the 23-valent pneumococcal polysaccharide vaccine (PPSV23) booster, as well as adult SOT recipients without seroprotection against HBV who then received the Engerix-B® booster after pre-transplantation vaccination. Logistic regression models were used to analyze risk factors for non-response to booster vaccination. Results: We included 50 SOT recipients in analyses of booster vaccination against IPD and 52 SOT recipients in analyses of booster vaccination against HBV. Seroprotection rates were 52% after booster vaccination against IPD and 7.7% after booster vaccination against HBV. The median geometric mean concentration of pneumococcal antibodies increased from 0.54 µg/mL IgG (interquartile range, IQR: 0.35–0.77) to 1.21 µg/mL IgG (IQR: 0.87–1.62) after booster vaccination (p < 0.001). Having pre-transplantation seroprotection against IPD at time of listing was associated with lower odds of non-response to booster vaccination. We were not able to identify risk factors for non-response to HBV booster vaccination. Conclusions: Booster vaccination improved seroprotection against IPD, but not HBV. Further studies are needed to examine optimal vaccination strategies for SOT recipients. Full article
(This article belongs to the Special Issue Hepatitis Vaccines: Safety, Efficacy and Global Impact)
Show Figures

Figure 1

16 pages, 249 KB  
Article
Seasonal Influenza Vaccination Uptake and Intentions Among Nursing Students in Hong Kong
by Maria Shuk Yu Hung, Grace Sun King Wan, Wai Hon Chua and Ching Man Cheng
Vaccines 2025, 13(12), 1252; https://doi.org/10.3390/vaccines13121252 - 17 Dec 2025
Viewed by 514
Abstract
Background/Objectives: Seasonal influenza is a global public health issue, and influenza vaccination is the most effective preventive measure. Nursing students are at a higher risk of contracting it due to clinical exposure. However, vaccination uptake among nursing students remains low. This study examines [...] Read more.
Background/Objectives: Seasonal influenza is a global public health issue, and influenza vaccination is the most effective preventive measure. Nursing students are at a higher risk of contracting it due to clinical exposure. However, vaccination uptake among nursing students remains low. This study examines seasonal influenza vaccination uptake rates and the predictors of nursing students’ willingness to receive this vaccine. Methods: A cross-sectional online study was conducted using a well-validated questionnaire in order to collect data from a convenience sample of nursing students in Hong Kong from early November to early December 2024. Results: Out of the 461 valid responses received, 67.5% were from females, with a mean age of 20.53 (SD = 2.16) years. Vaccination history was diverse: 34.3% reported that they underwent influenza vaccination in the most recent season, 49.7% reported that they were vaccinated one to two times over the preceding five years, and only 5% reported that they undergo vaccination annually. A logistic regression model showed that the respondents who had been vaccinated against influenza in the most recent years (OR = 2.881, 95% CI: 1.773–4.680) had been vaccinated against influenza 1–2 times (OR = 3.239, 95% CI: 1.750–5.993), had been vaccinated 3–4 times (OR = 3.984, 95% CI: 1.773–8.957), had been vaccinated every year (OR = 10.353, 95% CI: 3.025–35.436) in the past five years, and had a higher score of perceived susceptibility (OR = 2.244, 95% CI: 1.302–3.867) were more likely to intend to be vaccinated with an influenza vaccine in the coming year. Conclusions: Annual seasonal influenza vaccination rates among nursing students remain low, though they have improved. We recommend that the Hong Kong government, healthcare organizations, and universities develop effective strategies for promoting annual seasonal influenza vaccination to safeguard both patients’ health and the health of future nursing professionals. Full article
(This article belongs to the Section Vaccines and Public Health)
4 pages, 158 KB  
Editorial
Natural and Vaccine-Induced Immunity in the Post-Pandemic Era: Convergence, Divergence, and Unfinished Challenges
by Chloe Dimeglio
Vaccines 2025, 13(12), 1251; https://doi.org/10.3390/vaccines13121251 - 17 Dec 2025
Viewed by 478
Abstract
The global response to SARS-CoV-2 has advanced at unprecedented speed: vaccines developed in record time, mass immunization campaigns, and real-world data confirming reductions in severe disease and death [...] Full article
21 pages, 4109 KB  
Article
Retrospective Cohort Analysis of Survival After SARS-CoV-2 Infection by Vaccination Status in Jamaica, April–December 2021
by Karen Webster-Kerr, Andriene Grant, Ardene Harris, Eon Campbell, Deborah Henningham, Marsha Brown, Daidre Rowe, Carol Lord, Romae Thorpe, Tanielle Mullings, Jovan Wiggan, Nicole Martin-Chen, Tonia Dawkins-Beharie and Jacqueline Duncan
Vaccines 2025, 13(12), 1250; https://doi.org/10.3390/vaccines13121250 - 17 Dec 2025
Viewed by 408
Abstract
Background/Objectives: To estimate (a) survival after SARS-CoV-2 infection by COVID-19 vaccination status, and (b) COVID-19 vaccine effectiveness in a middle-income country. Methods: In this retrospective cohort study, secondary analysis of data from the national surveillance and vaccination databases was conducted. The primary outcome [...] Read more.
Background/Objectives: To estimate (a) survival after SARS-CoV-2 infection by COVID-19 vaccination status, and (b) COVID-19 vaccine effectiveness in a middle-income country. Methods: In this retrospective cohort study, secondary analysis of data from the national surveillance and vaccination databases was conducted. The primary outcome was COVID-19 death classified based on the WHO criteria. Data were analysed by vaccination status, age, sex, geographic region, and wave period. Kaplan–Meier curves were plotted; log-rank followed by multiple comparison tests were used to compare survival probabilities. Cox proportional-hazards models with time-varying covariates estimated hazard ratios (HR). Vaccine effectiveness was computed as (1-HR) × 100. Results: A total of 55,299 COVID-19 cases were captured by the national surveillance system between 1 April and 31 December 2021. Of these, 45,774 (1581 vaccinated, 44,193 unvaccinated) were included in the analysis. After a follow-up of 327 days, there were 22 deaths (case fatality rate (CFR) 1.5%) among 1581 COVID-19 vaccinated cases and 1821 deaths (CFR 4.1%) among 44,193 unvaccinated cases. There was one COVID-19 death per 10,000 person days in vaccinated cases compared with 2.7 COVID-19 deaths per 10,000 person days in unvaccinated cases. After adjustment for age, sex, and geographic region, the effectiveness against COVID-19 death across all vaccine types (ChAdOx1 nCoV-19, BNT162b2, Ad26.COV2.S, or BBIBP-CorV) was 68% (95% CI: 51–79). Effectiveness was 75% (95% CI: 59–84) for ChAdOx1 nCoV-19. Vaccine effectiveness across all vaccine types was higher in younger cases, (82% (95% CI: 52–93), 18–64 years vs. 63% (95% CI: 41–77), ≥65 years), females (84% (95% CI: 63–93), females vs. 53% (95% CI: 24–71), males) and those vaccinated in the past 3 months (71% (95% CI: 47–85), past 0–3 months vs. 56% (95% CI: 23–75), 3–6 months). Conclusions: COVID-19 vaccines were effective in preventing COVID-19 death in a population with low vaccination coverage. Limitations of the analysis include the use of surveillance data (under-reporting of cases, missing data), exclusion of partially vaccinated cases, and insufficient data on important confounders (circulating variants and comorbidities). Full article
(This article belongs to the Special Issue Inequality in Immunization 2025)
Show Figures

Figure 1

12 pages, 927 KB  
Article
The Mediating Role of Vaccine Hesitancy in Influenza Vaccination Uptake and Intention Among Older Adults in Urban China: Based on a Structural Equation Modeling Study
by Shuai Yuan, Yuxing Wang, Yuanruo Xie, Jianing Dai, Sean X. Leng and Lili You
Vaccines 2025, 13(12), 1249; https://doi.org/10.3390/vaccines13121249 - 16 Dec 2025
Viewed by 485
Abstract
Background: Influenza presents significant risks to older adults; however, vaccination coverage in China remains low despite robust recommendations. Factors such as vaccine hesitancy, physician recommendations, health status, and socioeconomic conditions influence vaccination rates. This study uses large-scale influenza vaccination data from urban [...] Read more.
Background: Influenza presents significant risks to older adults; however, vaccination coverage in China remains low despite robust recommendations. Factors such as vaccine hesitancy, physician recommendations, health status, and socioeconomic conditions influence vaccination rates. This study uses large-scale influenza vaccination data from urban older adults in six cities and applies structural equation modeling to investigate the determinants of both influenza vaccination uptake and future intention. Methods: A cross-sectional survey was conducted from December 2024 to January 2025 across six major Chinese cities, involving 13,363 community-dwelling adults aged ≥60 years. Vaccine hesitancy was measured using the validated 5C scale. Structural equation modeling with weighted least squares mean and variance adjusted estimation was employed to assess direct and indirect effects of physician recommendation, socioeconomic status, medical status, and subjective health on influenza vaccination uptake. Results: The vaccination uptake rate is 34.05%, while the intention rate is 32.20%. Vaccine hesitancy is the strongest negative predictor of vaccination (β = −0.488, p < 0.001). Physician recommendation has the largest total effect (β = 0.351), with 45.60% of this effect mediated through reduced vaccine hesitancy. Medical status is directly associated with lower uptake; it consistently promoted intention. Higher socioeconomic status also positively affected vaccination (total effect = 0.167), partly via lower hesitancy. Conclusions: Vaccine hesitancy serves as a pivotal mediator in influenza vaccination uptake and intention among Chinese older adults. Strengthening physician recommendations and addressing socioeconomic disparities are key strategies to reduce hesitancy and improve coverage. Full article
(This article belongs to the Special Issue Acceptance and Hesitancy in Vaccine Uptake: 2nd Edition)
Show Figures

Figure 1

18 pages, 1368 KB  
Article
Vaccine Platform-Dependent Differential Impact on Microbiome Diversity: Potential Advantages of Protein Subunit Vaccines
by Hye Seong, Jin Gu Yoon, Eliel Nham, Yu Jung Choi, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, Sooyeon Lim and Joon Young Song
Vaccines 2025, 13(12), 1248; https://doi.org/10.3390/vaccines13121248 - 15 Dec 2025
Viewed by 579
Abstract
Background: The COVID-19 pandemic accelerated the development of diverse vaccine platforms, including mRNA, adenoviral vector, and protein subunit vaccines. Given the growing evidence that the gut microbiome modulates vaccine-induced immunity, this study compared the effects of a protein subunit vaccine (NVX-CoV2373), an [...] Read more.
Background: The COVID-19 pandemic accelerated the development of diverse vaccine platforms, including mRNA, adenoviral vector, and protein subunit vaccines. Given the growing evidence that the gut microbiome modulates vaccine-induced immunity, this study compared the effects of a protein subunit vaccine (NVX-CoV2373), an mRNA vaccine (BNT162b2), and an adenoviral vector vaccine (ChAdOx1) on gut microbiome diversity following booster vaccination. Methods: We conducted a prospective cohort study involving 35 healthy adults who received an NVX-CoV2373 booster. Stool and blood samples were collected before vaccination and three weeks afterward. Gut microbiome profiles were analyzed using 16S rRNA gene sequencing, and the results were compared with our previous cohorts who received BNT162b2 or ChAdOx1 vaccines. Results: The NVX-CoV2373 booster was associated with a significant increase in the Shannon diversity index (p = 0.027), indicating enhanced alpha diversity. This finding contrasts with the decrease or absence of significant short-term change observed following repeated administrations of adenoviral vector and mRNA vaccines, respectively. Notably, NVX-CoV2373 vaccination was accompanied by an increased relative abundance of beneficial taxa such as Bacteroides fragilis and a decrease in Prevotella bivia. In comparison, repeated ChAdOx1 doses resulted in a sustained reduction in alpha diversity, whereas BNT162b2 showed a transient post-booster rise followed by a long-term decline in species richness. Conclusions: In the booster setting, the protein subunit vaccine NVX-CoV2373 exerted a distinct and favorable effect on gut microbiome diversity, increasing alpha diversity in contrast to the patterns observed with mRNA and adenoviral vector booster vaccines. Full article
(This article belongs to the Special Issue Human Immune Responses to Infection and Vaccination)
Show Figures

Figure 1

12 pages, 1388 KB  
Article
Inactivated Enterovirus 71 Particle Aggregation Stability: Dynamic Light Scattering Analysis and Stabilizer Identification
by Anna Yang, Dongsheng Yang, Deqin Pang, Jie Yang, Wenhui Wang, Yaxin Du, Xin Wan, Shengli Meng, Jing Guo and Shuo Shen
Vaccines 2025, 13(12), 1247; https://doi.org/10.3390/vaccines13121247 - 15 Dec 2025
Viewed by 364
Abstract
Background: Inactivated enterovirus 71 (EV71) vaccines play a vital role in preventing severe cases of hand, foot, and mouth disease, with their quality and stability determined by the degree of viral particle aggregation. Objective: This study aimed to use dynamic light scattering (DLS) [...] Read more.
Background: Inactivated enterovirus 71 (EV71) vaccines play a vital role in preventing severe cases of hand, foot, and mouth disease, with their quality and stability determined by the degree of viral particle aggregation. Objective: This study aimed to use dynamic light scattering (DLS) for monitoring EV71 particle size, comprehensively evaluate the effects of environmental stresses on viral aggregation, and identify suitable stabilizing agents. Methods: The DLS technique was validated. Using this method, the effects of pH, ionic strength, freeze–thaw cycles, temperature, and mechanical stresses on viral particle size were assessed. Additionally, the ability of different buffer salts and stabilizers to inhibit stress-induced aggregation was systematically evaluated. Results: The DLS method exhibited robust performance. EV71 particles were stable at pH 7.0–7.5. Exposure to 47 °C and magnetic stirring promoted viral aggregation. Phosphate buffer and citrate buffer exhibited the highest inhibitory effects on heat-induced aggregation and stirring-induced aggregation, respectively. M199 and Tween 80 efficiently mitigated heat-induced particle aggregation and shear stress-induced particle aggregation, respectively. Conclusions: This study demonstrated the performance of DLS in viral aggregation monitoring. Additionally, this study revealed tailored stabilization strategies, providing key insights for vaccine formulation and quality control. Full article
(This article belongs to the Special Issue Nanoparticle-Based Delivery Systems for Vaccines)
Show Figures

Graphical abstract

18 pages, 2197 KB  
Article
Long-Term Impact of Pneumococcal Conjugate Vaccines on the Burden of Pneumococcal Meningitis in Mozambique, 2013–2023
by Aquino Albino Nhantumbo, Goitom Weldegebriel, Linda de Gouveia, Reggis Katsande, Charlotte Elizabeth Comé, Alcides Moniz Munguambe, Vlademir Cantarelli, Cícero Dias, Rachid Muleia, Ezequias Fenias Sitoe, Eunice Veronica Zeca, Amir Seni, Ana Nicolau Tambo, Ana Cristina de Faria Neves Mussagi, Plácida Iliany Maholela, Ivano de Filippis and Eduardo Samo Gudo
Vaccines 2025, 13(12), 1246; https://doi.org/10.3390/vaccines13121246 - 15 Dec 2025
Viewed by 320
Abstract
Background: Mozambique introduced the 10-valent pneumococcal conjugate vaccine (PCV10) in 2013 using a three-dose primary series with no booster dose (3p+0) and later switched to the PCV13 using a schedule of two primary doses with one booster (2p+1). We aimed to describe the [...] Read more.
Background: Mozambique introduced the 10-valent pneumococcal conjugate vaccine (PCV10) in 2013 using a three-dose primary series with no booster dose (3p+0) and later switched to the PCV13 using a schedule of two primary doses with one booster (2p+1). We aimed to describe the burden and serotype distribution of pneumococcal meningitis in children under 5 years of age in Mozambique over an eleven-year period starting with the year of PCV10 introduction, and assess the impact of the PCV vaccine and schedule changes. Methods: We analysed meningitis surveillance data in Mozambique from March 2013 through to December 2023. Cerebrospinal fluid (CSF) samples were collected from eligible children in three referral hospitals (Maputo Central Hospital [south], Beira Central Hospital [central], and Nampula Central Hospital [north]). Culture and polymerase chain reaction assay (qPCR) were performed on each sample. S. pneumoniae-positive samples were subsequently serotyped using multiplex assay. We estimated annual incidence rates for pneumococcal meningitis in children under 5 years old following the PCVs’ introduction (2013–2023). The impact of the product switch and schedule change from PCV10/3p+0 to PCV13/2p+1 on the burden and serotype distribution of pneumococcal meningitis was assessed. Results: Of the 4075 CSF samples tested, 7.4% (301/4075) were positive for S. pneumoniae, 2.5% (103/4075) for H. influenzae, and 1.0% (42/4075) for N. meningitidis. Pneumococcal meningitis incidence in children under five reduced from 44.7 cases per 100,000 in 2013 to 4.6 cases per 100,000 in 2023, an 89.7% reduction. In the PCV13/2p+1 period (2020–2023), pneumococcal meningitis incidence was 51.2% lower than the PCV10/3p+0 period (2013–2017) (IRR 0.49, 95% CI 0.4–0.6; p < 0.001). PCV10-serotype pneumococcal meningitis incidence among children under five decreased by 65.6% in the PCV13/2p+1 period (IRR 0.34, 95% CI 0.2–0.6; p < 0.001). We detected zero cases of pneumococcal meningitis due to the PCV13-serotype in 2020–2023, whereas non-PCV10/13-serotypes increased by 76% (IRR 1.76, 95% CI 1.2–2.6; p = 0.004). The case–fatality proportion decreased by 71.9% (95% CI 62.9–84.8%) in the PCV13/2p+1 period. Conclusions: Since the introduction of PCVs in Mozambique, the burden of pneumococcal meningitis and deaths in children under 5 years of age has substantially decreased, as well as the prevalence of PCV13-serotypes. Higher valency PCVs are needed due to the increased prevalence of non-PCV10/13-serotypes. Funding: Gavi, The Vaccine Alliance, reference number: MOZ-HSS-2-INS; WHO Reference: 2014405143-0, creation DFC to support HIB & Surveillance System. Full article
(This article belongs to the Special Issue Pneumococcal Vaccines: Current Status and Future Prospects)
Show Figures

Figure 1

18 pages, 5483 KB  
Article
Molecular Surveillance Reveals F-Gene Mutations and Constrained G-Gene Evolution in Human Respiratory Syncytial Virus: Implications for Vaccine Efficacy in Saudi Arabia
by Mohamed A. Farrag, Ibrahim M. Aziz, Abdulaziz M. Almuqrin, Noorah A. Alkubaisi, Reem M. Aljowaie, Asma N. Alsaleh, Fatimah N. Alanazi, Adel A. Abdulmanea and Fahad N. Almajhdi
Vaccines 2025, 13(12), 1245; https://doi.org/10.3390/vaccines13121245 - 15 Dec 2025
Viewed by 630
Abstract
Background/Objectives: Human Respiratory Syncytial Virus (HRSV) is a major global cause of acute lower respiratory infections in children. With recent approval of pre-fusion F protein-based vaccines and monoclonal antibodies, ongoing molecular surveillance is critical. This study examined HRSV molecular epidemiology and evolution in [...] Read more.
Background/Objectives: Human Respiratory Syncytial Virus (HRSV) is a major global cause of acute lower respiratory infections in children. With recent approval of pre-fusion F protein-based vaccines and monoclonal antibodies, ongoing molecular surveillance is critical. This study examined HRSV molecular epidemiology and evolution in Riyadh, focusing on mutations in the attachment (G) and fusion (F) glycoproteins and their potential impact on vaccine efficacy. Methods: Nasopharyngeal aspirates (NPAs) (200 samples) were collected from pediatric patients. HRSV-positive samples were typed, and the G gene hypervariable region and F gene were sequenced. Sequence and phylogenetic analyses were performed to identify circulating genotypes and amino acid substitutions. Results: HRSV was detected in 15% of samples, with HRSV-B slightly predominant over HRSV-A. Infants aged 2–5 months had the highest incidence rate of infection. The ON1 subgenotype remained dominant. The duplicated region of the G gene showed constrained evolution, with 18 variable and 6 conserved residues over 13 years. In the F protein, HRSV-A isolates exhibited high conservation, with only three amino acid substitutions in antigenic sites (Ø and II). Sites III, IV, and V remained fully conserved. In contrast, HRSV-B isolates displayed eight substitutions in antigenic sites, including six in site II (palivizumab-binding epitope). Conclusions: Given the highly effective HRSV prophylactics, including the approved vaccines and monoclonal antibodies, these mutations raise critical concerns regarding vaccine efficacy against HRSV-B. These findings underscore the necessity of sustained, seasonal molecular surveillance to monitor the emergence of variants and provide a molecular basis for further clinical studies. Full article
(This article belongs to the Special Issue Recent Progress of Vaccines for Respiratory Syncytial Virus (RSV))
Show Figures

Graphical abstract

12 pages, 1441 KB  
Article
Integrated In Silico and In Vivo Evaluation of a Tetravalent SARS-CoV-2 RBD–Fc Fusion Vaccine with Broad Cross-Variant Antibody Responses
by Ahmad Bakur Mahmoud, Renad M. Alhamawi, Mustafa Yassin Taher, Awadh S. Alsubhi, Mekky M. Abouzied, Heba M. Zahid, Mohammed Abdullah Alotaibi, Nada Almarghalani, Khulood Alotaibi, Abdulrahman Habash, Shaker Ahmed Alsharif and Almohanad Alkayyal
Vaccines 2025, 13(12), 1244; https://doi.org/10.3390/vaccines13121244 - 15 Dec 2025
Viewed by 617
Abstract
Background/Objectives: SARS-CoV-2 continues to generate antigenically divergent variants that reduce the breadth of existing vaccine-induced antibody responses. Fc-fusion subunit vaccines offer advantages in stability, antigen display, and Fc-mediated immune engagement. This study aimed to design and evaluate a tetravalent RBD–Fc fusion construct incorporating [...] Read more.
Background/Objectives: SARS-CoV-2 continues to generate antigenically divergent variants that reduce the breadth of existing vaccine-induced antibody responses. Fc-fusion subunit vaccines offer advantages in stability, antigen display, and Fc-mediated immune engagement. This study aimed to design and evaluate a tetravalent RBD–Fc fusion construct incorporating RBDs from Wuhan-Hu-1 and Omicron BA.4/BA.5 and to determine whether this configuration can induce broad antibody recognition across SARS-CoV-2 variants. The objective was to assess its feasibility, biochemical properties, and initial immunogenicity. Methods: Immune responses to the construct were first assessed using the C-ImmSim simulation platform. The full-length fusion was synthesized, subcloned into pcDNA3.1(+), expressed in HEK293 cells, and purified by Protein G affinity chromatography. Protein integrity was evaluated by reducing SDS–PAGE. BALB/c mice (female, 8 weeks) were immunized with a prime–boost–boost schedule, and sera were analyzed by ELISA, considering binding to Wuhan-Hu-1, Omicron BA.4/BA.5, and a panel of RBD variants. Results: In silico analysis predicted coordinated antigen clearance, class switching, memory B- and CD4+ T-cell formation, and transient cytokine induction. The recombinant protein was expressed efficiently, yielding a major ~56 kDa band and a ~23 kDa RBD fragment. Vaccinated mice generated strong IgG responses to Wuhan-Hu-1 and BA.4/BA.5 RBDs and showed broad binding to major variant RBDs. Conclusions: The tetravalent RBD–Fc fusion vaccine was successfully produced and elicited broad antibody binding across SARS-CoV-2 variants, supporting its potential as a versatile protein-based vaccine platform. Full article
(This article belongs to the Section COVID-19 Vaccines and Vaccination)
Show Figures

Figure 1

18 pages, 7468 KB  
Article
An Evaluation of the Efficacy of Four Currently Used Sheep Pox Vaccines Against a Contemporary Virulent Strain
by Irina Shumilova, Mohammad Abed Alhussen, Alena Krotova, Kseniya Shalina, Pavel Prutnikov, Svetlana Kononova, Olga Byadovskaya, Ilya Chvala, Larisa Prokhvatilova and Alexander Sprygin
Vaccines 2025, 13(12), 1243; https://doi.org/10.3390/vaccines13121243 - 15 Dec 2025
Viewed by 493
Abstract
Background/Objectives: Sheep pox, a highly contagious disease, is prevalent in Africa and Asia, with sporadic outbreaks in Europe, and inflicts tremendous economic losses. Vaccination represents the primary and most effective prevention method. The genetic diversity of circulating SPPV strains worldwide is poorly studied, [...] Read more.
Background/Objectives: Sheep pox, a highly contagious disease, is prevalent in Africa and Asia, with sporadic outbreaks in Europe, and inflicts tremendous economic losses. Vaccination represents the primary and most effective prevention method. The genetic diversity of circulating SPPV strains worldwide is poorly studied, and vaccine selection is typically guided by the availability of a particular vaccine. In this study, four sheep pox vaccines, including the RM65, KSGP 0240, KSGP ARRIAH, and NISKHI ARRIAH vaccines, were evaluated against a contemporary virulent strain circulating in Asia. Methods: The level of antibodies in the blood serum was determined using the ELISA and microneutralization assay. Blood samples and nasal swabs were obtained for PCR examination. Comprehensive clinical and postmortem pathological examinations were conducted. Results: The body temperature of all experimental animals remained within the physiological norm, with no clinical manifestations, local reactions, viremia, or necropsy pathological lesions, demonstrating the effectiveness and safety of the vaccines used against the contemporary virulent strain. Furthermore, immunization was associated with the formation of neutralizing and specific antibodies in all vaccinated groups post vaccination, with a significant increase in their levels after challenge, indicating a high level of immunogenicity. The NISKHI ARRIAH vaccine exhibited statistically significant superiority over the other vaccinated groups. However, the unvaccinated control group demonstrated post-challenge moderate-to-severe clinical signs, postmortem lesions, with high levels of virus shedding, and lower levels of neutralizing and specific antibodies, compared with the vaccinated groups. Conclusions: Our study results indicate that the experimental group immunized with the NISKHI ARRIAH vaccine exhibited the initial and most substantial immune response, maintaining the highest antibody levels on the 28th day after vaccination in comparison to the other studied vaccines. Full article
(This article belongs to the Section Veterinary Vaccines)
Show Figures

Figure 1

13 pages, 4099 KB  
Article
Immunogenicity of HIV-1 Env-Gag VLP mRNA and Adenovirus Vector Vaccines in Mice
by Jing Yang, Qi Ma, Xiaozhou He, Hongxia Li, Xiaoguang Zhang, Yanzhe Hao and Xia Feng
Vaccines 2025, 13(12), 1242; https://doi.org/10.3390/vaccines13121242 - 14 Dec 2025
Viewed by 398
Abstract
Background/Objectives: In previous studies, we demonstrated that the HIV-1 Env-Gag VLP mRNA vaccine elicited superior cellular immune responses. In this study, we further evaluated the immunogenicity of the Env-Gag VLP mRNA and adenovirus vector vaccines when administered individually or in combination in mice. [...] Read more.
Background/Objectives: In previous studies, we demonstrated that the HIV-1 Env-Gag VLP mRNA vaccine elicited superior cellular immune responses. In this study, we further evaluated the immunogenicity of the Env-Gag VLP mRNA and adenovirus vector vaccines when administered individually or in combination in mice. Methods: BALB/c mice were divided into four groups and immunized twice at a 3-week interval. The three groups received either the Env-Gag VLP mRNA vaccine, the adenovirus vector vaccines expressing env and gag genes, or PBS as a control. The fourth group received a prime-boost regimen, primed with the Env-Gag mRNA vaccine and boosted with the adenovirus vector vaccines. The HIV-1 specific cellular and humoral immune responses were measured 1, 2, 4 and 8 weeks after the last immunization. Results/Conclusions: The results showed that the mRNA vaccines prime-adenovirus vector vaccines boost elicited higher cellular immune responses than those induced by homologous regimens at multiple time points, especially 8 weeks after the last immunization. Although the level of gp120 binding antibody in the combined immunization group is significantly lower than that of in the VLP mRNA vaccine group, a more balanced Th1/Th2 responses were induced in the combined immunization group, and significantly higher and longer-lasting neutralizing antibody levels were detected in this group making it a very promising HIV vaccine strategy. Full article
(This article belongs to the Special Issue Virus-Like Particle Vaccine Development)
Show Figures

Figure 1

16 pages, 2410 KB  
Article
Geographical Patterns of COVID-19 Vaccine Inequality by Race and Ethnicity and Sociodemographic Determinants of Health: Evidence from Louisville, Kentucky
by Seyed M. Karimi, Amir Hossein Hassani, Hamid Zarei, Mana Moghadami, Md Yasin Ali Parh, Shaminul H. Shakib, Venetia Aranha, Mohammad Mansouri, Trey Allen, Yuting Chen, Sirajum Munira Khan, Farzaneh Raoofi, Sepideh Poursafargholi, Taylor Ingram and Angela Graham
Vaccines 2025, 13(12), 1241; https://doi.org/10.3390/vaccines13121241 - 13 Dec 2025
Viewed by 410
Abstract
Background: Infectious diseases accounted for approximately 18.4% of global mortality in 2019. According to the World Health Organization (WHO), vaccines are available for about 30 potentially lethal diseases. Vaccination prevents substantial mortality and hospitalization. However, its ability to improve overall public health depends [...] Read more.
Background: Infectious diseases accounted for approximately 18.4% of global mortality in 2019. According to the World Health Organization (WHO), vaccines are available for about 30 potentially lethal diseases. Vaccination prevents substantial mortality and hospitalization. However, its ability to improve overall public health depends on equitable access across all populations, regardless of race, ethnicity, education, or socioeconomic status. Objectives: This study aims to examine how disparities in social determinants of health (SDOH) affect COVID-19 vaccination uptake across Jefferson County, Kentucky. Using ZIP code–level spatial mapping, this study investigates the intersection of SDOH, racial composition, and geographic characteristics to identify inequities and inform equitable interventions. Methods: Data from the Kentucky Immunization Registry (KYIR) were analyzed to assess two-dose COVID-19 vaccination rates at the ZIP code and regional levels in Jefferson County, Kentucky. Vaccination rates were stratified by race and ethnicity and linked with SDOH, including education, employment, insurance status, and income, obtained from the 2021 American Community Survey. Results: By May 2021, vaccination rates ranged from 25.9% in the West region to 57.0% in the Inner East region; by May 2022, these rates increased to 46.2% and 73.9%, respectively. White residents consistently had the highest two-dose vaccination rates (66.4% by May 2022), while Black and Hispanic residents had lower rates (45.7% and 43.9%, respectively). Vaccination rates were strongly correlated with SDOH, especially educational attainment, average family income, and employment rate, underscoring the role of socioeconomic inequities in vaccination disparities. Conclusions: Geographical and racial disparities emphasize the influence of social and economic inequality on vaccine uptake. Full article
(This article belongs to the Special Issue Vaccines and Vaccinations During and After the Pandemic Period)
Show Figures

Figure 1

13 pages, 310 KB  
Article
Incidence, Clinical Features and Vaccination Coverage of Pneumococcal Disease in People Living with HIV: A Retrospective Cohort Study (2015–2024)
by Pere Medina, Elisa de Lazzari, Mateu Espasa, Lorena de la Mora, María Martínez-Rebollar, Ana González-Cordón, Montserrat Laguno, Alexy Inciarte, Juan Ambrosioni, Júlia Calvo, Alberto Foncillas, Abiu Sempere, Ivan Chivite, Leire Berrocal, Jose Luis Blanco, Esteban Martínez, José M. Miró, Josep Mallolas and Berta Torres
Vaccines 2025, 13(12), 1240; https://doi.org/10.3390/vaccines13121240 - 13 Dec 2025
Viewed by 406
Abstract
Introduction: The incidence of pneumococcal disease (PD) in people living with HIV (PLWH) is higher than in the general population; therefore, this study aimed to analyze its incidence, clinical characteristics and vaccination coverage in PLWH. Methods: We conducted a retrospective, single-center study between [...] Read more.
Introduction: The incidence of pneumococcal disease (PD) in people living with HIV (PLWH) is higher than in the general population; therefore, this study aimed to analyze its incidence, clinical characteristics and vaccination coverage in PLWH. Methods: We conducted a retrospective, single-center study between 2015 and 2024 in Hospital Clínic, Barcelona, involving HIV patients who presented with PD during the study period (any patient with a microbiologically confirmed result). A descriptive analysis of cases was carried out and compared with patients who did not present PD during the study period. Results: A total of 177 episodes of PD were identified in 148 individuals, with a cumulative incidence of 1.7% (95% CI: 1.4–2.0). The median age at PD diagnosis was 45.9 (36–53) years; 64% of patients were Spanish-born; 50% of patients were men who have sex with men (MSM); the HIV transmission mode was intravenous drug use in 28% of cases; the median CD4 nadir was 181 (58–324) cells/mm3; the median CD4 prior to PD was 429 (240–663) cells/mm3; and the median peak HIV viral load (VL) was 176,839 (20,900–502,000) copies/mL. Intravenous drug use (OR 3.43; 95% CI 2.19–5.36; p < 0.001), peak HIV VL (OR 1.11; 95% CI 1.02–1.21; p = 0.011), and CD4 nadir (OR 0.92; 95% CI 0.87–0.98; p = 0.005) were independently associated with PD, and fifty-one percent of patients had not received any vaccination prior to their PD episode. Conclusion: PD incidence was high in our study and associated with poor immunological status. Research on new strategies to improve vaccination coverage and immunogenicity in PLWH is needed. Full article
(This article belongs to the Special Issue A One-Health Perspective on Immunization Against Infectious Diseases)
Show Figures

Figure 1

19 pages, 601 KB  
Review
StealthX: A Versatile and Potent Exosome-Based Vaccine Platform for the Next Pandemic
by Minghao Sun and Kristi Elliott
Vaccines 2025, 13(12), 1239; https://doi.org/10.3390/vaccines13121239 - 13 Dec 2025
Viewed by 502
Abstract
Exosome-based vaccines represent a transformative platform in modern vaccinology, combining nanoscale delivery, biocompatibility, and potent immunogenicity. Among these, the StealthX platform developed by Capricor, Inc. has demonstrated exceptional versatility, enabling antigen presentation at nanogram level doses without the need for adjuvants. Preclinical studies [...] Read more.
Exosome-based vaccines represent a transformative platform in modern vaccinology, combining nanoscale delivery, biocompatibility, and potent immunogenicity. Among these, the StealthX platform developed by Capricor, Inc. has demonstrated exceptional versatility, enabling antigen presentation at nanogram level doses without the need for adjuvants. Preclinical studies using StealthX have shown strong humoral and cellular immune responses against SARS-CoV-2 variants, including Delta and Omicron, as well as broader applications against influenza and RSV antigens. The platform’s ability to accommodate multiple antigens within a single formulation addresses the challenges of viral variation and facilitates multivalent “mix-and-match” immunization strategies. This review offers an in-depth evaluation of the StealthX vaccine platform, covering the biological mechanisms underlying exosome function, the engineering approaches used to load antigens, and preclinical results demonstrated across three pivotal studies. By synthesizing current evidence, this review underscores the platform’s applicability for emerging infectious diseases and explores the strategic value of multivalent exosome-based vaccines in global immunization efforts as an emerging next-generation vaccine technology. Full article
(This article belongs to the Special Issue Host–Virus Interactions and Vaccine Development)
Show Figures

Figure 1

14 pages, 3911 KB  
Article
Characterization and Vaccine Development of Vibrio anguillarumAeromonas salmonicida salmonicida and Aeromonas salmonicida masoucida Isolated from Salmonids in Republic of Korea
by Youngjun Park, Sungjae Ko, Hyun-Ja Han, Myoung Sug Kim, Soo Ji Woo and Suhee Hong
Vaccines 2025, 13(12), 1238; https://doi.org/10.3390/vaccines13121238 - 12 Dec 2025
Cited by 1 | Viewed by 490
Abstract
Background/Objectives: This study aimed to characterize Vibrio anguillarum strain 23FBVib0271 (VA) isolated from rainbow trout and Aeromonas salmonicida salmonicida strain 17FBASa0016 (ASS) and A. salmonicida masoucida strain 23FBAer0174 (ASM) isolated from Atlantic salmon in the Republic of Korea. Their physiological traits, pathogenicity, [...] Read more.
Background/Objectives: This study aimed to characterize Vibrio anguillarum strain 23FBVib0271 (VA) isolated from rainbow trout and Aeromonas salmonicida salmonicida strain 17FBASa0016 (ASS) and A. salmonicida masoucida strain 23FBAer0174 (ASM) isolated from Atlantic salmon in the Republic of Korea. Their physiological traits, pathogenicity, and antigenicity were examined, and formalin-inactivated vaccines were developed to evaluate safety and immunogenicity in Atlantic salmon (Salmo salar). Methods: Formalin-inactivated VA, ASS and ASM were administered intraperitoneally, and protective efficacy was determined after six weeks. Serum biochemical parameters (AST, ALT, ALP, glucose) and histopathology were analyzed for safety. ELISA and real-time PCR targeting IL-1β, BCL6, membrane-bound IgM, and secretory IgM were performed to assess immune responses. Results: Vaccination provided relative percent survivals of 100%, 75%, and 95% for VA, ASS and ASM, respectively, without adverse physiological or histological effects. Immunological analyses revealed strong antibody production and upregulation of immune-related genes. Conclusions: Formalin-inactivated vaccines from VA, ASS and ASM are safe and effectively induce protective humoral immunity in Atlantic salmon by promoting antigen-specific antibody responses and immune gene activation. Full article
(This article belongs to the Section Vaccine Advancement, Efficacy and Safety)
Show Figures

Figure 1

19 pages, 307 KB  
Review
Toward Universal Protection: A Comprehensive Review of Pneumococcal Disease, Emerging Vaccination Challenges and Future Perspectives
by Mayla Sgrulletti, Maria Felicia Mastrototaro, Alessandra Beni, Gloria Mantuano, Giorgio Costagliola, Veronica Santilli, Davide Montin, Caterina Rizzo, Baldassarre Martire, Gian Luigi Marseglia, Michele Miraglia Del Giudice, Viviana Moschese and Immunology (SIAIP) Vaccine Committee
Vaccines 2025, 13(12), 1237; https://doi.org/10.3390/vaccines13121237 - 12 Dec 2025
Viewed by 617
Abstract
Streptococcus pneumoniae contributes significantly to morbidity, mortality, and healthcare costs worldwide due to severe Invasive Pneumococcal Disease (IPD), particularly among young children and vulnerable populations. This review critically examines the current state of pneumococcal disease epidemiology, the evolution of vaccine strategies, and persistent [...] Read more.
Streptococcus pneumoniae contributes significantly to morbidity, mortality, and healthcare costs worldwide due to severe Invasive Pneumococcal Disease (IPD), particularly among young children and vulnerable populations. This review critically examines the current state of pneumococcal disease epidemiology, the evolution of vaccine strategies, and persistent challenges to achieve global control of the disease. The implementation of Pneumococcal Conjugate Vaccines (PCVs) has yielded substantial public health gains, establishing herd protection and sharply reducing vaccine-type IPD incidence. However, this success has been fundamentally challenged by serotype replacement, where non-vaccine serotypes have subsequently emerged to cause a significant proportion of the residual disease burden. This epidemiological shift has necessitated the development and deployment of higher-valency PCVs (PCV15, PCV20, and PCV21) to expand serotype coverage. Furthermore, optimal protection requires personalized strategies for high-risk cohorts where vaccine effectiveness can be compromised. In this context, the review details how pneumococcal vaccination—and particularly PPSV23—serves as an indispensable diagnostic tool to evaluate a broad spectrum of Inborn Errors of Immunity (IEI) and in particular humoral defects. Diagnostic challenges are strained by non-standardized assays and the limited panel of unique serotypes available for testing in the PCV era. The scientific priority is now the development of universal protein-based vaccines, to provide protection against all serotypes and non-encapsulated strains by targeting conserved virulence factors. This integrated approach, combining expanded PCV coverage with novel vaccine technology, is essential to mitigate the ongoing public health burden of pneumococcal disease. Full article
Show Figures

Graphical abstract

16 pages, 239 KB  
Article
Knowledge, Attitude, and Practices of Paediatricians in the West Bank, Palestine, Regarding COVID-19 Vaccination Among Children Younger than 12 Years: A Cross-Sectional Study, October to November 2023
by Yousef Mosleh, Kostas Danis, Pawel Stefanoff and Diaa Hjaija
Vaccines 2025, 13(12), 1236; https://doi.org/10.3390/vaccines13121236 - 11 Dec 2025
Viewed by 360
Abstract
Background/Objectives: Paediatricians’ recommendations influence parental decisions to vaccinate their children. On 19 January 2022, the World Health Organization authorized the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) under Emergency Use Listing for children under 12 years as a measure to mitigate disease spread and direct [...] Read more.
Background/Objectives: Paediatricians’ recommendations influence parental decisions to vaccinate their children. On 19 January 2022, the World Health Organization authorized the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) under Emergency Use Listing for children under 12 years as a measure to mitigate disease spread and direct protection for children with underlying conditions. We assessed knowledge, attitudes, and practices (KAP) of Palestinian paediatricians regarding COVID-19 vaccination for children under 12 years and identified factors affecting support for vaccination. Methods: From 1 October to 8 November 2023, we surveyed paediatricians across the West Bank using structured telephone interviews. We collected data on sociodemographic characteristics and KAP regarding COVID-19 vaccination and calculated KAP scores from eight, nine, and nine items, respectively, with total scores categorized as poor/moderate/good. We performed bivariable and multivariable analyses to identify factors associated with paediatricians supporting COVID-19 vaccination for children under 12 years. Results: Of the 367 eligible paediatricians, 323 (88%) responded; the median age was 51 years (range: 28–70); 27% supported COVID-19 vaccination for children. Mean scores for knowledge (range 0–8), attitude (0–9), and practice (0–9) were 3.0 ± 2.1, 3.9 ± 2.4, and 4.0 ± 1.7, respectively. The mean overall KAP score (0–26) was 11 ± 4.8. Safety and efficacy concerns and lack of long-term data were the main reasons for hesitancy. Higher knowledge scores (PR = 1.8, 95% CI: 1.3–2.5, p = 0.001) and positive attitudes (PR = 1.6, 95% CI: 1.1–2.3, p = 0.01) were significantly associated with paediatricians’ support for vaccination. After adjustment for other factors, participants with regular continuing medical education attendance (aPR = 1.4, 95% CI: 1.0–2.6, p = 0.045), trusting WHO recommendations (aPR = 3.1, 95% CI: 1.4–7.8, p = 0.047), having a positive attitude score (aPR = 1.3, 95% CI: 0.4–4.4, p = 0.041), and a good total KAP score (aPR = 1.1, 95% CI: 1.0–1.2, p = 0.044) supported COVID-19 vaccination for children. Conclusions: Support for COVID-19 vaccination among Palestinian paediatricians was low, associated with their knowledge, attitudes, and trust in health authorities. The revised WHO recommendations from 10 November 2023, decreasing the priority of vaccinating healthy children, could influence the opinion of paediatricians. However, the low support for COVID-19 vaccinations could affect the performance of other vaccination programmes and should be carefully addressed through targeted education. Full article
(This article belongs to the Special Issue Acceptance and Hesitancy in Vaccine Uptake: 2nd Edition)
16 pages, 800 KB  
Article
COVID-19 Vaccine Effectiveness Against Mortality in the Omicron Period: Evidence from Linked Mortality and Vaccination Records
by Sadia Farzana, Francesco Maria Rossi, Katie S. Allen, Qian Luo, Jeff Whittle, Kevin McGurk, Benjamin W. Weston, Andy Ye Yuan, Ali Moghtaderi, Vladimir Atanasov and Bernard Black
Vaccines 2025, 13(12), 1235; https://doi.org/10.3390/vaccines13121235 - 11 Dec 2025
Viewed by 1197
Abstract
Objective: This study aimed to assess COVID-19 vaccine effectiveness against death (VE), controlling for healthy vaccinee bias. Methods: We link all adult deaths through year-end 2022 in the State of Indiana, U.S.A., to vaccination records and identify which deceased received primary vaccination (measured [...] Read more.
Objective: This study aimed to assess COVID-19 vaccine effectiveness against death (VE), controlling for healthy vaccinee bias. Methods: We link all adult deaths through year-end 2022 in the State of Indiana, U.S.A., to vaccination records and identify which deceased received primary vaccination (measured as either one or two initial doses) and which received one or two booster doses. We measure COVID-19 mortality with the COVID Excess Mortality Percentage (CEMP). CEMP is calculated, for a group defined by various characteristics (age, sex, time period), as COVID-19 deaths divided by non-COVID natural deaths. The CEMP outcome measure accounts for healthy vaccinee bias by using non-COVID natural mortality to control for differences in population health. Results: We find a large healthy vaccinee bias. Controlling for this bias, we find substantial VE for primary vaccination and the first booster dose during the first five vaccine-available calendar quarters, from 1Q2021 through 1Q2022 (end of Omicron infection wave). However, over 2Q–4Q2022, we find no evidence for primary-vaccination VE, and find moderate but statistically insignificant booster VE, which largely wanes by 4Q2022. Conclusions: It is known that by 2Q2022, most people had natural immunity from prior COVID-19 infection. Thus, our results for 2Q–4Q2022 largely reflect comparing hybrid (infection plus vaccination) immunity to infection-only immunity. In this period, we find negligible mortality benefit from primary vaccination, and moderate but waning benefit from a booster dose. Policy Implications: Controlling for healthy vaccinee bias is crucial when estimating VE. We found limited VE against COVID-19 mortality over 2Q–4Q2022, but lacked data for more recent periods. Full article
Show Figures

Figure 1

4 pages, 161 KB  
Editorial
SARS-CoV-2, Influenza and Other Respiratory Viruses: Epidemiology, Burden of Disease, and Preventive Measures
by Emma Papini, Saverio Caini and Marco Del Riccio
Vaccines 2025, 13(12), 1234; https://doi.org/10.3390/vaccines13121234 - 10 Dec 2025
Viewed by 969
Abstract
Four years after the acute COVID-19 emergency, respiratory viruses circulate in overlapping seasonal patterns that repeatedly test surveillance systems and healthcare capacity [...] Full article
11 pages, 225 KB  
Article
Evaluating the Influenza Vaccination Knowledge Among People Living in a Rural and Medically Underserved Community of Washington State
by Damianne Brand, Kimberly McKeirnan, Megan Giruzzi and Juliet Dang
Vaccines 2025, 13(12), 1233; https://doi.org/10.3390/vaccines13121233 - 9 Dec 2025
Viewed by 434
Abstract
Background/Objectives: Health literacy and vaccine literacy influence vaccine uptake behavior. Ensuring that people in rural communities are knowledgeable about vaccines can be an important tool in increasing influenza vaccination rates. The goal of this research was to evaluate rural community member knowledge [...] Read more.
Background/Objectives: Health literacy and vaccine literacy influence vaccine uptake behavior. Ensuring that people in rural communities are knowledgeable about vaccines can be an important tool in increasing influenza vaccination rates. The goal of this research was to evaluate rural community member knowledge of influenza and influenza vaccine. Methods: A cross-sectional survey was conducted with residents of a rural a medically underserved community in Washington State. Three thousand rural residents were contacted up to five times by a survey research center with a request to participate, with the goal of receiving 500 returned surveys based on the current population size, a z-score of 95, and an error rate of 5%. The survey evaluated rural resident knowledge and opinions about influenza and influenza vaccine. Results: Participants who were vaccinated against influenza in the last five years were more likely to know that influenza vaccine does not cause influenza (χ2 = 13.44, p < 0.01) and that antibiotics cannot be used to treat influenza (χ2 = 19.36, p < 0.01) than people who were not vaccinated. There was no statistical difference between people who are vaccinated and unvaccinated regarding knowing that influenza is viral rather than bacterial with the majority in both groups responding correctly (χ2 = 0.05, p < 0.82), or that people who have influenza are at higher risk for contracting pneumonia (χ2 = 0.78, p = 0.08) or COVID-19 (χ2 = 1.54, p = 0.21). Unvaccinated people were more likely to have had their opinion about vaccines changed in recent years (p < 0.01) and feel that COVID-19 impacted their ability to trust public health officials (p < 0.01). Conclusions: Understanding gaps that exist in rural resident knowledge about influenza could be valuable in developing future educational outreach efforts in these communities. Full article
26 pages, 3353 KB  
Article
Evaluation of Polymyxin B as a Novel Vaccine Adjuvant and Its Immunological Comparison with FDA-Approved Adjuvants
by Mahek Gulani, Yash Harsoda, Tanisha Arte, Martin J. D’Souza, Priyal Bagwe, Emmanuel Adediran, Nigel D’Souza and Dedeepya Pasupuleti
Vaccines 2025, 13(12), 1232; https://doi.org/10.3390/vaccines13121232 - 9 Dec 2025
Viewed by 597
Abstract
Background: Adjuvants enhance the immune response to antigens incorporated in vaccine formulations. Given that the majority of infectious agents enter the body through mucosal surfaces, efficacious vaccines must generate protective immunity at these sites, which serve as the first line of defense. There [...] Read more.
Background: Adjuvants enhance the immune response to antigens incorporated in vaccine formulations. Given that the majority of infectious agents enter the body through mucosal surfaces, efficacious vaccines must generate protective immunity at these sites, which serve as the first line of defense. There is a need for mucosal adjuvants; hence, we explored the potential of repurposing existing drugs with established safety profiles in humans. Polymyxins are a class of clinically used antibiotics. They are cationic peptides and mast cell activators, which are a novel class of vaccination adjuvants. The goal was to assess the adjuvant properties of Polymyxin B microparticles in combination with vaccine candidates previously developed in our laboratory, such as microparticulate gonorrhea, influenza, measles, Zika, and canine coronavirus vaccines, and to compare their performance with FDA-licensed adjuvants, such as MF59 and Alum. Methods: Polymyxin microparticles were formulated using a double emulsion method, and the toxicity profile and autophagosome generation of Polymyxin B microparticles were assessed. The immunogenic potential of Polymyxin B in these vaccines was studied using multiple parameters such as nitric oxide release using Griess assay and immune profiling using flow cytometry for markers such as MHC I, MHC II, CD40, and CD80. Results: Polymyxin B microparticles were found to be non-cytotoxic to dendritic cells up to 500 μg/mL. Polymyxin B promoted autophagosome formation and nitric oxide release, and showed the upregulation of MHC I, MHC II, CD80, and CD40 pathways. Conclusions: The adjuvant activity of Polymyxin B across various vaccine platforms is significantly comparable to FDA-approved adjuvants, which is a critical requirement for generating T cell responses such as helper T cell and cytotoxic CD8+ T cell responses. Full article
(This article belongs to the Special Issue Bioengineering in Vaccine Design and Delivery)
Show Figures

Figure 1

24 pages, 2621 KB  
Review
Personalized Cancer Vaccines: Current Advances and Emerging Horizons
by Lantian Lu, Xuehan Lu and Wei Luo
Vaccines 2025, 13(12), 1231; https://doi.org/10.3390/vaccines13121231 - 8 Dec 2025
Viewed by 1837
Abstract
Personalized cancer vaccines represent a revolutionary frontier in oncology, harnessing the unique genetic and molecular profile of individual tumors to elicit targeted immune responses. This review provides a comprehensive overview of the current landscape and future perspectives of neoantigen-based personalized cancer vaccines, encompassing [...] Read more.
Personalized cancer vaccines represent a revolutionary frontier in oncology, harnessing the unique genetic and molecular profile of individual tumors to elicit targeted immune responses. This review provides a comprehensive overview of the current landscape and future perspectives of neoantigen-based personalized cancer vaccines, encompassing peptide, mRNA, DNA, autologous dendritic cell, and viral or bacterial vector platforms. We further discuss the integration of immune adjuvants, delivery systems, and combinational strategies, particularly with immune checkpoint inhibitions, to overcome tumor-induced immune exhaustion and improve therapeutic efficacy. Despite significant clinical progress over the past decade in this space, major challenges remain in immunogenic neoantigens prediction, streamlining individualized vaccine manufacturing, and optimization of combinational regimens to maximize durable antitumor responses. By reviewing recent preclinical and clinical studies on neoantigen-based cancer vaccines, this review highlights key advances, identifies persistent translational bottlenecks, and underscores the need for biomarker-guided mechanistically informed trials to fully unleash the clinical potential of neoantigen-based personalized cancer vaccines in the era of precision immuno-oncology. Full article
(This article belongs to the Special Issue Personalised Cancer Vaccines)
Show Figures

Figure 1

15 pages, 4454 KB  
Article
Colloidal Manganese Salt Improves the Efficacy of Toxoplasma gondii Inactivated Vaccine in Mice
by Chebing Huang, Shaoyuan Bai, Haiqiong Yu, Ming Pan, Zhaofeng Hou, Lizhi Fu and Siyang Huang
Vaccines 2025, 13(12), 1230; https://doi.org/10.3390/vaccines13121230 - 7 Dec 2025
Viewed by 455
Abstract
Background/Objectives: Toxoplasmosis caused by Toxoplasma gondii still poses a serious threat to public health in most countries and regions. Currently, the lack of effective vaccines necessitates the urgent development of a safe and effective vaccine. Methods: In this study, we combined the inactivated [...] Read more.
Background/Objectives: Toxoplasmosis caused by Toxoplasma gondii still poses a serious threat to public health in most countries and regions. Currently, the lack of effective vaccines necessitates the urgent development of a safe and effective vaccine. Methods: In this study, we combined the inactivated T. gondii vaccine with a colloidal manganese salt (Mn jelly [MnJ]) adjuvant. Results: This triggered a powerful innate immunity, significantly increased the number of CD4+ and CD8+ T cells secreting interferon γ (IFN-γ) in mice, and enhanced the generation of CD8+ central memory T cells and CD8+ effector memory T cells. Compared to the control groups, mice in experimental groups produced more specific IgG, and produced high levels of IL-2, IL-12 and IFN-γ. The survival rate of mice in experimental groups reached 50%, while all control group mice died within 9 days during T. gondii acute infection. Furthermore, the burden of brain cysts in experimental group mice was also significantly reduced by 90.77% compared to the control group during chronic infection. Conclusions: These results suggested that the incorporation of an MnJ adjuvant significantly enhances the immunoprotective efficacy of inactivated T. gondii vaccine, positioning this formulation as a promising candidate for development against toxoplasmosis. Full article
(This article belongs to the Section Vaccine Advancement, Efficacy and Safety)
Show Figures

Figure 1

15 pages, 935 KB  
Article
Coverage and Drivers of Vaccinations in Patients with Autoimmune Rheumatic Diseases: An Italian Multicentric Study
by Ilaria Anna Bellofatto, Valentino Paci, Fabrizio Conti, Gianluca Santoboni, Gian Domenico Sebastiani, Maria Sofia Cattaruzza, Camilla Mazzanti, Simonetta Salemi, Giorgio Sesti, Emanuele Tesoriere, Valerio Fiorilli, Imma Prevete, Francesca Romana Spinelli and Andrea Picchianti Diamanti
Vaccines 2025, 13(12), 1229; https://doi.org/10.3390/vaccines13121229 - 6 Dec 2025
Viewed by 624
Abstract
Background: Patients with autoimmune rheumatic diseases (ARDs) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are at increased risk of infections due to immune dysregulation and immunosuppressive therapy. Vaccination is a cornerstone of infection prevention, but uptake is still inadequate. Methods: [...] Read more.
Background: Patients with autoimmune rheumatic diseases (ARDs) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are at increased risk of infections due to immune dysregulation and immunosuppressive therapy. Vaccination is a cornerstone of infection prevention, but uptake is still inadequate. Methods: We conducted an observational, multicenter study at four Italian rheumatology centers. Adult patients with RA or SLE on immunosuppressive therapy completed a standardized questionnaire assessing demographics, disease activity, treatments, vaccination status for influenza, pneumococcus, varicella-zoster virus [VZV], hepatitis B virus [HBV], human papillomavirus [HPV], adverse events, and reasons for or against vaccination. Results: A total of 325 patients were included (226 RA, 99 SLE; median age 60 years; 84.6% females). Overall vaccine coverage was 68.0%, with influenza being the most frequent (54.2%), followed by pneumococcal (30.8%), HBV (21.2%), VZV (12.9%) and HPV (5.9%). RA patients showed higher influenza and pneumococcal uptake, while HBV vaccine was more common in SLE. Education was associated with higher pneumococcal and HBV coverage in both groups. Major adverse events and disease flares were rare. Physician recommendation was the main motivator, with rheumatologists driving VZV uptake and general practitioners influencing influenza and HBV. Among unvaccinated patients, the leading barrier was not being offered vaccination (42.5%), followed by concerns about efficacy/safety (18.3%) and lack of awareness (15.7%). Cluster analysis identified three subgroups: “Not offered” (largest), “Unaware,” and “Skeptical,” with age distribution differing across clusters. Conclusions: Vaccination coverage among Italian ARD patients remains insufficient. Physician recommendation is pivotal, while lack of physician offer and awareness are major barriers. Targeted educational strategies and proactive physician involvement are needed to improve vaccine uptake in this high-risk population. Full article
Show Figures

Figure 1

17 pages, 1312 KB  
Article
Avian Immunoglobulin Y Antibodies Targeting the Protruding or Shell Domain of Norovirus Capsid Protein Neutralize Norovirus Replication in the Human Intestinal Enteroid System
by Ming Xia, Mohamed Ichou, Mathew Landivar, Peng Zhou, Sai Navya Vadlamudi, Alice Leruth, Charlotte Nyblade, Paul Cox, Lijuan Yuan, Julius Goepp and Ming Tan
Vaccines 2025, 13(12), 1228; https://doi.org/10.3390/vaccines13121228 - 5 Dec 2025
Viewed by 580
Abstract
Background: Norovirus is a leading cause of epidemic acute gastroenteritis worldwide, associated with significant morbidity, mortality, and economic loss. Despite its global impact, no licensed vaccine is currently available, and vaccine development remains challenging. Methods: We explored avian immunoglobulin Y (IgY) antibodies as [...] Read more.
Background: Norovirus is a leading cause of epidemic acute gastroenteritis worldwide, associated with significant morbidity, mortality, and economic loss. Despite its global impact, no licensed vaccine is currently available, and vaccine development remains challenging. Methods: We explored avian immunoglobulin Y (IgY) antibodies as a low-cost countermeasure against norovirus infection. We generated recombinant protruding (P) domain proteins from the capsid protein (VP1) of noroviruses, representing two GII.4 variants and the GII.6 genotype. These were combined into a single immunogen to immunize laying hens to produce norovirus VP1-specific IgY antibodies. Results: Immunization of laying hens with the P domain proteins elicited high-titer (>1:450,000) P domain-specific IgY antibodies. The yolk-derived IgY effectively inhibited binding of various norovirus P particles to their histo-blood group antigen ligands, with 50% blocking titers (BT50) up to 1:8533 against homotypic GII.4 and 1:667 against heterotypic G1.1 Norwalk virus P particles. Importantly, the IgY neutralized replication of GII.4 norovirus in the human intestinal enteroid (HIE) system at a high titer of over 1:2500, equivalent to 0.70 µg/mL of total IgY. We also produced norovirus shell (S) domain proteins and corresponding IgY antibodies, which neutralized GII.4 norovirus replication in the HIE model at a titer of ~1:800, equivalent to 2.98 µg/mL of total IgY. This provides the first evidence that the S domain contains neutralizing epitopes. Conclusions: Our findings support the potential of IgY targeting norovirus P or S domains as a scalable, cost-effective strategy for preventing norovirus infection and disease. Full article
(This article belongs to the Special Issue New Approaches to Vaccine Development and Delivery)
Show Figures

Figure 1

Previous Issue
Next Issue
Back to TopTop